Search bioRxiv⌕ Search

Biology subjects

Muley, H.

Publications and source records attributed to Muley, H..

2 recordsLinked to original sources

Label-Free Live Cell Type Prediction by Integrating Raman Spectroscopy and Machine Learning

Coherent Raman spectroscopy enables label-free biochemical fingerprinting of live cells with subcellular resolution. We previously developed a machine learning framework capable of classifying glioma FFPE tissues using Raman spectral signatures. To accelerate live cell acquisition, we previously developed RADAR (Raman Spectral Analysis Using Deep Learning for Artifact Removal), a method that increases imaging speed by an order of magnitude while preserving spectral integrity. By integrating high-speed Raman imaging with supervised machine learning, we aimed to define unique biochemical fingerprints specific to cell type. We hypothesized that intrinsic biochemical composition alone is sufficient to distinguish cellular identity and tumor subtype. To test this, we generated metabolic maps of diverse brain-derived cell types--including astrocytoma, oligodendroglioma, and glioblastoma cells--using coherent Raman spectroscopy at single-cell resolution. Patient-derived brain tumor cell lines representing genetically heterogeneous backgrounds were analyzed. Samples were stratified by IDH1 mutation status (IDH1-mutant and IDH1-wild-type) and histologically classified as oligodendroglioma or astrocytoma. Raman spectral data were acquired from 286 live single cells across the two principal molecular classes, with further subdivision into two histologic subtypes within the IDH1-mutant group. Classification was performed using an XGBoost model with shallow tree depth (1-3), a 20% held-out test set, and grouped, stratified 5-fold cross-validation to control for sample-level bias. The machine learning framework distinguished IDH1-mutant from IDH1-wild-type cells with a ROC-AUC of 0.78 and further discriminated IDH1-mutant astrocytoma from oligodendroglioma cells with a ROC-AUC of 0.81. Feature importance analysis demonstrated that separation between IDH1-mutant and IDH1-wild-type cells was driven primarily by Raman peaks associated with protein amide bands, total NADH, unsaturated fatty acids, and heme-related vibrational modes. Within the IDH1-mutant class, discrimination between oligodendroglioma and astrocytoma was driven by lipid-rich vesicle signatures, protein/polyamide amide bands, and lipid-associated spectral features. Together, these findings support the feasibility of label-free, machine learning-assisted Raman profiling to resolve clinically relevant glioma subtypes at single-cell resolution. This scalable analytical framework provides a translational platform for investigating metabolic heterogeneity, therapeutic response, co-culture systems, and patient-derived organoid models.

cancer biology↗

SCD1 inhibition synergizes with TMZ to improve IDH1 MUT glioma survival of mice via lipotoxic stress

Mutations in the isocitrate dehydrogenase enzyme (IDH1) are prevalent in low-grade gliomas, such as oligodendrogliomas. Other than surgery, radiation, and chemotherapy, few options for treatment exist. The standard of care for patients currently consists of maximal safe resection, as well as the potential use of radiation and chemotherapy, typically followed by radiographic surveillance. Although significant advances have been achieved, these have not translated into meaningful improvements in overall survival, warranting the development of novel therapies. Herein, we demonstrate that the inhibition of SCD1 in vitro leads to decreased colony formation and is more specific to IDH1MUT glioma than the IDH1WT cells, We further identified MF-438 as an active inhibitor of this enzyme and showed that this inhibitor is linked with iron transport and ferroptosis. MF438 depleted oleic (C18:1) and palmitoleic acid (C16:1) levels, driving saturated phosphatidylcholine (PC) accumulation and ER stress (INSIG1, SEL1L upregulation). TS603 exhibited selective polyunsaturated phosphatidylcholine reduction with downregulation of GPX4, FTH1, and KEAP1, and upregulation of NCOA4, SLC11A2, ALDH7A1, and DPP4, consistent with ferroptosis priming via ferritinophagy-driven expansion of the labile iron pool, as confirmed by FerroOrange flow cytometry. Neutral lipid metabolism genes (LPIN1, LDLR, PNPLA3, ACSL1), intracellular lipid transport genes (TMEM41B, OSBP, STARD4), and lipid droplet organization genes (SQLE, CHKA, AUP1) were coordinately upregulated in TS603 after treatment with MF-438. MF438+TMZ activated the integrated stress response (ATF3, DDIT3, IRF1, CDKN1A, GADD45B) and synergistically suppressed TS603 neurosphere growth (p=0.0326). In vivo combination between MF-438 and TMZ showed improved survival versus the TMZ-alone group, in an IDH1-mutant oligodendroglioma model. Tissue analyses showed significant reduced Ki67 expression, a marker of cellular proliferation, in the combination treatment. Collectively, these findings suggest that targeting lipid metabolism may enhance the efficacy of standard-of-care therapy in IDH1-mutant oligodendroglioma.

Cancer Biology↗